An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

NCT01818921 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Over-weight
Prader-Willi Syndrome

Interventions

DRUG: ZGN-440 sterile diluent
DRUG: 1.2 mg ZGN-440 for injectable suspension
DRUG: 1.8 mg ZGN-440 for injectable suspension

Sponsor

Zafgen, Inc.